Q-omics provides the consensus-scored SLIT3-AS2 profile across patient tissues and cancer cell-line models. SLIT3-AS2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLIT3-AS2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SLIT3-AS2 RNA expression shows 14,338 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, COAD, and BRCA as cancer lineages where SLIT3-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLIT3-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLIT3-AS2 survival associations across molecular data types. SLIT3-AS2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLIT3-AS2 RNA expression–survival associations across cancer types. High SLIT3-AS2 expression shows unfavorable associations in KIRC and THCA, but favorable associations in BRCA, ESCA, BLCA and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLIT3-AS2 RNA expression.
This table summarizes SLIT3-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLIT3-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLIT3-AS2 shows lower tumor expression in COAD, BLCA, READ, KICH, LUSC and CHOL. The COAD box plot shows higher SLIT3-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.739, t-test p < 0.001).
This table shows molecular features associated with SLIT3-AS2 in patient tissues and cancer cell lines. In patient samples, SLIT3-AS2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
